CASI Pharmaceuticals Files 6-K, Incorporates Exhibits
Ticker: CASIF · Form: 6-K · Filed: May 16, 2025 · CIK: 1962738
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
TL;DR
CASI Pharma filed a 6-K on 5/16/25, linking exhibits to its F-3 registration statements.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on May 16, 2025, incorporating by reference information from Exhibit 99.1 into its existing F-3 Registration Statements (File Nos. 333-283998 and 333-). The company, formerly known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023, is based in Beijing, China.
Why It Matters
This filing indicates ongoing regulatory and corporate actions by CASI Pharmaceuticals, potentially impacting its securities and investor relations.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previously submitted information, not announcing new material events.
Key Numbers
- 001-41666 — SEC File Number (Identifies the company's filing with the SEC.)
- 333-283998 — F-3 Registration Statement File Number (Links incorporated exhibits to an active registration statement.)
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- May 16, 2025 (date) — Filing Date
- Exhibit 99.1 (document) — Incorporated Information
- Form F-3 (document) — Registration Statement Type
- 333-283998 (registration_number) — F-3 File Number
- CASI Pharmaceuticals Holdings, Inc. (company) — Former Company Name
- January 18, 2023 (date) — Name Change Date
- Beijing, China (location) — Company Headquarters
FAQ
What specific information is contained in Exhibit 99.1 that is being incorporated by reference?
The filing does not specify the content of Exhibit 99.1, only that it is being incorporated by reference into the Company's Registration Statements on Form F-3.
What is the purpose of incorporating Exhibit 99.1 into the Form F-3 registration statements?
Incorporation by reference allows information previously filed or submitted to be considered part of a new filing, often for ongoing securities offerings or updates.
When did CASI Pharmaceuticals, Inc. change its name from CASI Pharmaceuticals Holdings, Inc.?
The company's name was changed on January 18, 2023.
What is the principal executive office address of CASI Pharmaceuticals, Inc.?
The principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Is this filing related to a new securities offering?
The filing incorporates information into existing Form F-3 registration statements, which are often used for ongoing or future securities offerings, but this specific 6-K does not announce a new offering.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 16, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).